On Sept. 30, 2021, RELIEF THERAPEUTICS reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, had issued a press release providing a safety update on ZYESAMI(TM) (RLF-100(TM)/aviptadil) which tested in the ACTIV-3b/TESICO (Therapeutics for Severely Ill Inpatients with COVID-19) phase three study sponsored by the National Institutes of Health.

In its second scheduled analysis, the study’s Independent Data Safety Monitoring Board found no new safety concerns after reviewing a total of 231 patients and recommended continued enrollment.